Clinical trial NCT03116828: A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
Official title: Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Epilepsy With Partial On-set Seizures
Keywords: epilepsy
seizures
partial on-set seizures
Lead sponsor: Sumitomo Pharma America, Inc.
Sponsor class: INDUSTRY
First posted: 2017-04-17
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Arm 1 (ESL as first add-on) Arm 2 (ESL as later add-on)
Primary purpose: TREATMENT

Brief summary: A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures

Detailed description: This is a 31-week, multicenter, 2-arm, prospective, open-label, non-randomized, Phase 4 study of eslicarbazepine acetate (ESL) as adjunctive therapy in adult subjects with a diagnosis of epilepsy with POS. Two groups of ESL-naïve subjects will be evaluated. The groups are defined as follows:

* Arm 1 (ESL as first add-on): This group will include subjects who have been maintained on a regimen consisting of a stable dose of LEV or LTG for at least 1 month (28 days) prior to screening and who have not used any adjunctive treatment.
* Arm 2 (ESL as later add-on): This group will include subjects who have been maintained on a regimen consisting of a stable dose of 1-2 AEDs (excluding oxcarbazepine \[OXC\]) for at least 1 month (28 days) prior to screening and who have used adjunctive treatment in the past.

The Arm 1 subjects will allow an assessment of the efficacy and safety of ESL in subjects who are early in the course of their disease and being treated with one of the most common first line AEDs.

The subjects in Arm 2 are similar to the subject population in the ESL Phase 3 adjunctive epilepsy studies, treatment-resistant subjects who are later in the course of their disease. The inclusion of these subjects in the present study will provide an assessment of the efficacy and safety of ESL as a later adjunctive therapy in a real world clinical setting.

In addition, this study will provide data from both Arm 1 and Arm 2 for several behavioral, mood-related, and QOL-related assessments that were not evaluated in the ESL Phase 3 adjunctive epilepsy program.

The study will consist of a Screening Phase of 1 to 2 weeks, followed by a 2-week Titration Phase, a 24-week Maintenance Phase, and a Safety Follow-up/Taper Phase of 4 weeks. The last visit in the Maintenance Phase (Visit 9) is considered the End of Study (EOS) visit

Eligibility criteria: Inclusion Criteria:

1. Male or female subjects ≥ 18 years of age.
2. Subject is willing and able to sign informed consent.
3. Subject has a documented diagnosis of epilepsy with simple POS with a motor component or complex POS with or without secondarily generalized seizures as defined in the Classification of Seizures of the International League Against Epilepsy
4. Subject has a documented electroencephalogram within 10 years prior to screening.
5. Subject has had at least 3 POS during previous six months.
6. Subject has had a sufficient number of seizures at time of enrollment to justify adjunctive therapy, as determined by the Investigator.
7. Subjects are required to be ESL-naïve AND

   1. Maintained on a stable LEV or LTG regimen for at least 1 month (28 days) prior to screening with no history of adjunctive treatment (for Arm 1, ESL as first add-on).

      OR
   2. Maintained on a stable dose of 1-2 AEDs (excluding OXC) for at least 1 month (28 days) prior to screening and who have had prior adjunctive treatment (for Arm 2, ESL as later add-on).
8. If the subject is treated with any stimulation device for epilepsy Vagal Nerve Stimulation (VNS), Responsive Neurostimulator (RNS), or similar, the device must have been implanted at least 6 months before screening and the device parameters must be documented as stable for at least 1 month prior to screening. (Note: These devices will not be counted as concomitant AED).
9. Except for epilepsy, subject is judged to be in general good health based on medical history, physical examination findings, and clinical laboratory

Exclusion Criteria:

1. Subjects with a prior exposure to ESL.
2. Subjects currently being treated with OXC.
3. Subject with a history of allergic reaction to OXC or CBZ, or a history of serious allergic reaction (Stevens-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or similar) to any AED, or a history of serious allergic reactions to other medications.
4. Subjects who have taken warfarin, felbamate, vigabatrin, or perampanel, (unless at stable dose with safety testing for ≥ 1 year) within a 4-week period prior to screening.
5. Subjects taking ezogabine

   .
6. Subject has taken any medication prohibited for this protocol within 4 weeks prior to Screening
7. Subjects using benzodiazepines on more than an occasional basis (defined as more than 2 times per week), except when used chronically as an AED
8. Seizure disorder characterized primarily by simple POS without motor signs.
9. Subject has a history of primarily generalized seizures (eg, myoclonic, absence, tonic).
10. Subject has a history of status epilepticus or cluster seizures (ie, 3 or more seizures within 30 minutes) within the 3 months prior to screening.
11. Subject has had seizures of psychogenic origin or purely subjective seizures within the last 2 years.
12. Subject has had seizures too close to count accurately.
13. Subject has a known progressive structural central nervous system (CNS) lesion, progressive encephalopathy or any other condition that may result in epilepsy secondary to a cerebral abnormality.
14. Subject whose current seizures are related to an acute medical illness or other non-epileptic origin.
15. Subjects of Asian ancestry will be excluded if they are carriers of HLA-B\*1502. Either:

    1. Subject must give written informed consent for genotyping, and test negative. OR
    2. Subjects must provide documentation of prior testing confirming non-carrier status.
16. Subject has a major medical illness other than epilepsy that would prevent safe participation in this study, at the discretion of the Investigator, including (but not limited to) cardiac disease, thyroid disease, hepatic or renal impairment, endocrine or metabolic disease, gastrointestinal disease, or hematologic disease. Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. If the effect of the condition in regard to the risk to the subject or to the study results is unclear, the Medical Monitor should be consulted.
17. Subjects with clinically relevant laboratory abnormalities at screening (eg, sodium \< 130 mEq/L, alanine transaminase (ALT) or aspartate transaminase (AST) \> 2.0 times the upper limit of the normal, white blood cell \[WBC\] count \< 3,000 cells/mm3, estimated creatinine clearance \< 50 mL/min, or has values for thyroid testing (free triiodothyronine (T3), free thyroxine (T4), thyroid stimulating hormone \[TSH\]) indicating the presence of significant thyroid dysfunction.
18. Subject has a history or presence of abnormal electrocardiogram (ECG), which in the Investigator's opinion is clinically significant or QT interval corrected for heart rate using the Fridericia method (QTcF) of ≥ 450 msec per screening ECG.
19. Subject has second or third-degree atrioventricular block that is not corrected with a pacemaker.
20. Subjects who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th edition text revision defined criteria for major depressive episode within the last 6 months. Subjects with mild, chronic depression without recent hospitalization who are being maintained on a stable dose of a single antidepressant are acceptable.
21. Subject has an active suicidal plan or intent (in the Investigator's opinion) in the past 4 weeks prior to screening.
22. Subject has a history of suicide attempt in the last 2 years prior to screening.
23. Subject has other major psychiatric disorders.
24. Subjects who are not able to complete the diary in the Investigator's opinion.
25. Subject has a history of alcohol or substance abuse within 2 years prior to screening for study participation, or subjects currently using alcohol, drugs of abuse, or any prescribed or over-the-counter medication in a manner, which, in the opinion of the Investigator, indicates abuse.
26. Subject tests positive for drugs of abuse at screening. Note: Subjects with a positive drug screen for marijuana, amphetamines, opiates, or benzodiazepines, who have a documented prescription for a medical condition and are on a stable dose of this prescribed medication for at least 4 weeks prior to screening, may be eligible to participate in the study upon approval from the Medical Monitor.
27. Subject is pregnant, currently nursing, or intends to become pregnant during the study period or within 30 days of the last dose of study drug.
28. Subject has participated in any investigational study within 30 days prior to screening, as documented in subject's medical history.
29. Subject is a clinical or investigational site staff member or relative of a staff member.
30. Any other condition or circumstance that, in the opinion of the Investigator, may compromise the subject's ability to comply with the study protocol.

Primary outcomes:
measure: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase
timeFrame: From the date of the first dose of the study drug until the completion of 24 weeks Maintenance Phase
Secondary outcomes:
Other outcomes:
Locations:
city: Mobile
country: United States
facility: University of South Alabaa Neurology Department
state: Alabama
city: Phoenix
country: United States
facility: Banner University Medical Center Phoenix=Neuroscience Institute
state: Arizona
city: Downey
country: United States
facility: Rancho Research Institute, Inc.
state: California
city: Fresno
country: United States
facility: Neuro-Pain Medical Center
state: California
city: La Jolla
country: United States
facility: Altman Clinical and Translational Research Institute
state: California
city: Orange
country: United States
facility: University of California-Irvine
state: California
city: Englewood
country: United States
facility: Blue Sky Neurology, a Division of Carepoint PC
state: Colorado
city: Farmington
country: United States
facility: University of Connecticut School of Mwdicine -UCONN Health
state: Connecticut
city: Washington
country: United States
facility: George Washington Medical Faculty Associates
state: District of Columbia
city: Boca Raton
country: United States
facility: Boca Raton Regional Hospital, Marcus Neuroscience Institute
state: Florida
city: Hollywood
country: United States
facility: Infinity Clinical Research, LLC
state: Florida
city: Maitland
country: United States
facility: Neurology Associates PA
state: Florida
city: Miami
country: United States
facility: The Neurology Research Group, LLC
state: Florida
city: North Palm Beach
country: United States
facility: Laszlo J. Mate, MD, PA
state: Florida
city: Orlando
country: United States
facility: Neurological Services of Orlando, PA
state: Florida
city: Orlando
country: United States
facility: Pedicatric Neurology, PA
state: Florida
city: Port Charlotte
country: United States
facility: Medsol Clinical Research Center
state: Florida
city: Tallahassee
country: United States
facility: Tallahassee Neurological Clinic
state: Florida
city: Tampa
country: United States
facility: University of South Florida
state: Florida
city: Vero Beach
country: United States
facility: Vero Beach Neurology And Reasearch Institue/The MS Center of Vero Beach
state: Florida
city: Suwanee
country: United States
facility: Georgia Neurology and Sleep Medicine Associates
state: Georgia
city: Honolulu
country: United States
facility: Hawaii Pacific Neuroscience
state: Hawaii
city: Boise
country: United States
facility: Conslutants in Epilepsy & Neurology, PLLC
state: Idaho
city: Chicago
country: United States
facility: Northwestern Medical Group, Deparment of Neurology
state: Illinois
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
city: Lexington
country: United States
facility: Associates in Neurology, PSC
state: Kentucky
city: Lexington
country: United States
facility: University of Kentucky Hospital, Chandler Medical Center
state: Kentucky
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Bethesda
country: United States
facility: Mid-Atlantic Epilepsy and Sleep Center
state: Maryland
city: Waldorf
country: United States
facility: Balijeet Shethi, MD
state: Maryland
city: Detroit
country: United States
facility: Wayne State University/Detroit Medical Center
state: Michigan
city: Golden Valley
country: United States
facility: Minneapolis Clinic of Neurology
state: Minnesota
city: Saint Paul
country: United States
facility: Minnesota Epilepsy Group, PA
state: Minnesota
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
city: Edison
country: United States
facility: JFK Neuroscience Institute, JFK Medical Center
state: New Jersey
city: Voorhees
country: United States
facility: Clinical Research Center of NJ (CRCNJ)
state: New Jersey
city: Mineola
country: United States
facility: NYU Winthrop Hospital, Clinical Trials Center
state: New York
city: Chapel Hill
country: United States
facility: UNC Inverstigal Drug Services
state: North Carolina
city: Charlotte
country: United States
facility: The Neurological Institute, PA
state: North Carolina
city: Winston-Salem
country: United States
facility: Wake Forest Baptist Health Sciences, Department of Neurology
state: North Carolina
city: Cincinnati
country: United States
facility: University of Cincinnati Medical Center
state: Ohio
city: Oklahoma City
country: United States
facility: Sooner Clinical Research
state: Oklahoma
city: Medford
country: United States
facility: Providence Medical Group-Medford Neurology
state: Oregon
city: Hershey
country: United States
facility: Penn State Hershey Medical Center
state: Pennsylvania
city: Philadelphia
country: United States
facility: Drexel University
state: Pennsylvania
city: Philadelphia
country: United States
facility: Temple University Lewis Katz School of Medicine
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Alleghany General Hospital (Allegheny Neurological Association)
state: Pennsylvania
city: Nashville
country: United States
facility: Vanderbilt Epilepsy Clinic
state: Tennessee
city: Austin
country: United States
facility: Austin Epilepsy Care Center
state: Texas
city: Dallas
country: United States
facility: Aston Ambulatory Care Center
state: Texas
city: San Antonio
country: United States
facility: University of Texas Health Science Center at San Antonio Medical Arts and Research Center
state: Texas
city: Madison
country: United States
facility: SSM Health Dean Medical Group
state: Wisconsin
city: London
country: Canada
facility: Londo Health Sciences Centre, University Hospital
state: Ontario
city: Greenfield Park
country: Canada
facility: Clinique D'Épilepsie Neuro Rive-Sud
state: Quebec
Study officials:
affiliation: Sumitomo Pharma America, Inc.
name: Sr. Director Medical Affairs
role: STUDY_CHAIR
References: